Galcanezumab-gnlm Injection
Galcanezumab-gnlm is a monthly injectable medication used to prevent migraine and treat episodic cluster headache in adults.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Galcanezumab-gnlm Injection: Patient Information Guide
A plain-language walkthrough of Galcanezumab-gnlm Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Galcanezumab-gnlm (brand name Emgality) is a prescription injection approved for adults for the following uses:
- Emgality — Preventive treatment of migraine: Taken on a regular monthly schedule to reduce the frequency of migraines. This is not a treatment you take when a migraine has already started.
- Emgality — Treatment of episodic cluster headache: Started at the beginning of a cluster period and given monthly until that cluster period ends, to reduce the attacks during that cycle.
⚙️How it works▾
Galcanezumab-gnlm is a humanized monoclonal antibody — a specially engineered protein that targets a specific molecule in the body. It binds directly to calcitonin gene-related peptide (CGRP), a signaling protein believed to play a central role in starting migraines and cluster headaches. By latching onto CGRP and blocking it from reaching its receptor, galcanezumab-gnlm interrupts the process before it can trigger a headache attack.
💊How it's taken▾
Emgality is given as a subcutaneous injection (under the skin) and is designed for self-injection at home using a prefilled pen or prefilled syringe. For migraine prevention, there is a higher starting dose given as two consecutive injections, followed by one injection once a month. For episodic cluster headache, a higher dose is given as three consecutive injections at the start of the cluster period, then one injection monthly until the cluster period ends.
- Inject into the abdomen, thigh, back of the upper arm, or buttocks — avoid skin that is tender, bruised, red, or hard
- Let Emgality sit at room temperature for 30 minutes before injecting; do not shake or apply heat
- If you miss a dose, give it as soon as you can, then resume your monthly schedule from that date
- Follow your prescriber's instructions exactly — the dosing schedule differs between migraine and cluster headache
🤒Side effects — in detail▾
The most commonly reported side effect with Emgality is injection site reactions — things like pain, redness, itching, or irritation where the shot was given. Here are the side effects to be aware of:
- Injection site pain, redness, itching, or reaction
- Constipation (which can, in rare cases, become severe)
- Rash
More serious reactions — including severe allergic reactions (anaphylaxis), significant swelling (angioedema), serious constipation requiring hospitalization, new or worsening high blood pressure, and Raynaud's phenomenon (color changes and pain in fingers or toes) — have been reported after Emgality was approved. Seek medical attention immediately if you experience trouble breathing, severe swelling, or any of these serious signs.
⚠️Warnings & precautions▾
- Serious allergic reactions: Anaphylaxis and angioedema have been reported. Reactions can occur days after an injection and may be prolonged. Stop using Emgality and get emergency help if you have trouble breathing, swelling of the face or throat, or severe hives.
- Serious constipation: Some people have developed severe constipation requiring hospitalization or even surgery, most often after the first dose. Tell your doctor right away if you develop significant constipation. Risk may be higher if you take other medications that slow gut movement.
- High blood pressure (hypertension): New or worsening high blood pressure has been reported, most commonly within the first week of starting treatment. Your doctor should monitor your blood pressure, and Emgality may need to be stopped if it cannot be controlled.
- Raynaud's phenomenon: Color changes, pain, or numbness in the fingers or toes have been reported, sometimes with serious outcomes including hospitalization. Symptoms typically appeared after about 10 weeks of treatment. Tell your doctor immediately if this happens; stopping Emgality often leads to improvement.
🔀What it interacts with▾
The FDA label for Emgality does not list specific drug-drug interactions. However, one important caution involves medications that slow digestion:
- Medications that reduce gut movement (gastrointestinal motility): Using these at the same time as Emgality may increase the risk of severe constipation or related complications — let your doctor know all medications you take.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Serious allergy to galcanezumab-gnlm or its ingredients: Emgality is contraindicated — do not use it if you have had a serious allergic reaction to it before.
- History of constipation or use of medications that slow digestion: Higher risk of serious constipation; discuss with your doctor.
- High blood pressure or risk factors for it: Emgality can trigger or worsen high blood pressure; monitor closely.
- History of Raynaud's phenomenon: Emgality may cause or worsen this condition; inform your doctor and watch for symptoms.
- Pregnancy: There are no adequate human studies. A pregnancy registry is available — ask your doctor about enrolling. Women with migraine may have a higher risk of preeclampsia during pregnancy.
- Breastfeeding: It is unknown whether Emgality passes into breast milk; weigh the benefits and risks with your doctor.
- Children and adolescents: Safety and effectiveness in pediatric patients have not been established.
- Adults 65 and older: Clinical studies did not include enough older adults to draw firm conclusions; use with appropriate monitoring.
- Kidney or liver problems: These are not expected to significantly affect how the body handles Emgality, but discuss your full health history with your prescriber.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous injection, Emgality reaches its peak level in the bloodstream in about 5 days, regardless of where on the body the injection is given. The drug stays active for a long time — its half-life (the time it takes for half the drug to leave the body) is approximately 27 days, which is why monthly dosing works. The body breaks galcanezumab-gnlm down into small peptides and amino acids, the same way it processes its own natural antibodies.
Age, sex, body weight, race, and kidney or liver function do not meaningfully change how Emgality behaves in the body, so no dose adjustments are typically needed for these factors.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect EMGALITY from light until use. Do not freeze. stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days.
📄 Written from Galcanezumab-gnlm Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Galcanezumab-gnlm Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Emgality do — does it stop a migraine once it starts? ▾
How do I give myself this injection at home? ▾
What side effects should I expect, and which ones mean I should call someone right away? ▾
What if I forget a dose? ▾
Is it safe to take Emgality if I'm pregnant or trying to get pregnant? ▾
How long does it take for Emgality to start working? ▾
Is Galcanezumab-gnlm Injection available over the counter? ▾
When was Galcanezumab-gnlm Injection first available? ▾
💬 Answers drafted from Galcanezumab-gnlm Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Galcanezumab-gnlm Injection comes
Galcanezumab-gnlm Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Emgality is used to prevent migraine in adults
- Emgality is used to treat episodic cluster headache in adults during a cluster period
- Emgality is injected subcutaneously (under the skin) in the abdomen, thigh, back of the upper arm, or buttocks
- Emgality comes as a single-dose prefilled pen or single-dose prefilled syringe — both deliver the full dose and are intended for self-administration
- Before injecting Emgality, let it sit at room temperature for 30 minutes; do not shake it or warm it with heat sources such as hot water or a microwave
- Do not use Emgality if the solution is cloudy or contains visible particles; protect it from direct sunlight
📊 Galcanezumab-gnlm Injection across the U.S. market
How Galcanezumab-gnlm Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Galcanezumab-gnlm Injection is used
A general measure of how commonly Galcanezumab-gnlm Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Galcanezumab-gnlm Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Galcanezumab-gnlm Injection prescribed? Of the 1,596 medications we measure, Galcanezumab-gnlm Injection ranks #323 by Medicaid prescriptions — more than 80% of them.
Utilization by Galcanezumab-gnlm Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector Most dispensed
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2058872
1 ML galcanezumab-gnlm 120 MG/ML Prefilled Syringe
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2058885
1 ML galcanezumab-gnlm 100 MG/ML Prefilled Syringe
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2170611
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Galcanezumab-gnlm Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 7 listed Galcanezumab-gnlm Injection NDCs with Medicaid activity.
🔍 Compare Galcanezumab-gnlm Injection products
A representative set of FDA-listed product records for Galcanezumab-gnlm Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/mL | — | Eli Lilly and Company | DRUG FOR FURTHER PROCESSING | View NDC → |
| 100 mg/mL | Subcutaneous | Eli Lilly and Company × 2 listings | BLA | View NDC → |
| 120 mg/mL | Subcutaneous | Eli Lilly and Company × 4 listings | BLA | View NDC → |
| 120 mg/mL | — | Eli Lilly and Company × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
Showing 9 of 9 products — FDA National Drug Code Directory. See every product, package size and price: browse all 9 Galcanezumab-gnlm Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Galcanezumab-gnlm Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Galcanezumab-gnlm Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Galcanezumab-gnlm Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2058846 2 dose forms · 3 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2058871In current FDA listingsClinical drug / strength (SCD) 1 ML galcanezumab-gnlm 120 MG/MLRxCUI 2058872 -
Dose form (SCDF) Prefilled Syringe RxCUI 2058884No current FDA listingClinical drug / strength (SCD) 1 ML galcanezumab-gnlm 100 MG/MLRxCUI 21706111 ML galcanezumab-gnlm 120 MG/MLRxCUI 2058885
Look up RxCUI 2058846 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Galcanezumab-gnlm Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Galcanezumab-gnlm Injection belongs to the Calcitonin gene-related peptide (CGRP) antagonists class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Eli Lilly and Company is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.